Quote | Ensysce Biosciences Inc. (NASDAQ:ENSC)
Last: | $0.575 |
---|---|
Change Percent: | 3.93% |
Open: | $0.562 |
Close: | $0.575 |
High: | $0.6 |
Low: | $0.56 |
Volume: | 32,462 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Ensysce Biosciences Inc. (NASDAQ:ENSC)
2024-05-28 08:48:18 ET More on Ensysce Biosciences Ensysce Biosciences reports Q4 results Read the full article on Seeking Alpha For further details see: Ensysce Biosciences regains Nasdaq compliance
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutio...
Message Board Posts | Ensysce Biosciences Inc. (NASDAQ:ENSC)
Subject | By | Source | When |
---|---|---|---|
nsysce Biosciences Announces Successful Completion of Ground-Breaking Study | subslover | investorshub | 05/09/2023 1:27:57 PM |
Time for a bounce? | PennyPusher786 | investorshub | 05/04/2023 7:09:57 PM |
$ENSC great article | PennyPusher786 | investorshub | 05/04/2023 3:41:14 PM |
news out | Shift-4 | investorshub | 04/30/2023 8:47:52 PM |
should we be shorting? | Hercules1 | investorshub | 04/29/2023 5:04:07 PM |
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutio...
PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmac...
~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative...